Price T Rowe Associates Inc Crinetics Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,590,504 shares of CRNX stock, worth $159 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,590,504

Previous 5,112,360 9.35%

Holding current value

$159 Million

Previous $171 Million 6.23%

% of portfolio

0.02%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$25.56 - $33.76 $12.2 Million - $16.1 Million	478,144 Added 9.35%	5,590,504 $161 Million
Q1 2025 May 14, 2025	SELL	$32.3 - $53.15 $9.76 Million - $16.1 Million	-302,145 Reduced 5.58%	5,112,360 $171 Million
Q4 2024 Feb 14, 2025	BUY	$50.66 - $60.69 $23.8 Million - $28.5 Million	469,748 Added 9.5%	5,414,505 $277 Million
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $23.6 Million - $29.6 Million	538,301 Added 12.22%	4,944,757 $253 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $24.6 Million - $30.3 Million	583,238 Added 15.26%	4,406,456 $197 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $28.3 Million - $38.1 Million	814,360 Added 27.07%	3,823,218 $179 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $11 Million - $16 Million	430,659 Added 16.7%	3,008,858 $107 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $18.4 Million - $35.2 Million	1,149,289 Added 80.43%	2,578,199 $76.7 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $21.8 Million - $32.7 Million	1,387,127 Added 3319.84%	1,428,910 $25.8 Million
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $155,365 - $214,122	-10,148 Reduced 19.54%	41,783 $672,000
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $150,314 - $184,861	-9,704 Reduced 15.74%	51,931 $951,000
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $130,899 - $161,690	7,228 Added 13.29%	61,635 $1.21 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $277,427 - $465,015	16,824 Added 44.76%	54,407 $1.02 Million
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $672,948 - $1.11 Million	-39,239 Reduced 51.08%	37,583 $825,000
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $206,251 - $302,822	10,659 Added 16.11%	76,822 $2.18 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $4,017 - $6,004	238 Added 0.36%	66,163 $1.39 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $271,254 - $360,819	17,060 Added 34.91%	65,925 $1.24 Million
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $426,092 - $562,249	-32,037 Reduced 39.6%	48,865 $747,000
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $977,296 - $1.41 Million	80,902 New	80,902 $1.14 Million

Others Institutions Holding CRNX

# of Institutions

233

Shares Held

90M

Call Options Held

59.7K

Put Options Held

14.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.53B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Crinetics Pharmaceuticals, Inc. Transaction History